Cancer stem‐like cell properties are regulated by EGFR/AKT/β–catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma. (8th April 2013)

• Record Type: Journal Article
• Authors: Ma, Lei; Zhang, Gong; Miao, Xiao‐Bo; Deng, Xu‐Bin; Wu, Yue; Liu, Ying; Jin, Zhi‐Ru; Li, Xi‐Qing; Liu, Qiu‐Zhen; Sun, Du‐Xin; Testa, Joseph R.; Yao, Kai‐Tai; Xiao, Guang‐Hui
• Is Part Of: FEBS journal. Volume 280:Number 9(2013)
• Page Start: 2027
• Page End: 2041
• Publication Date: 2013-04-08
• Subjects: Biochemistry -- Periodicals; Molecular biology -- Periodicals; Pathology, Molecular -- Periodicals; 572
• DOI: 10.1111/febs.12226
• Languages: English
• ISSNs: 1742-464X

Abstract

<abstract abstract-type="main" id="febs12226-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <p>We report that the epidermal growth factor receptor (EGFR) pathway plays a critical role in regulating cancer stem‐like cells (CSCs) in nasopharyngeal carcinoma (NPC), one of the most common malignant tumors in Southeast Asia. Effects of EGFR on maintaining CSCs are mainly mediated by AKT signaling, and β–catenin is responsible for governing CSC properties in response to EGFR/AKT activation. Significantly, CSCs are enriched by cisplatin and decreased by gefitinib in NPC xenograft models. Upon reimplantation in secondary mice, tumor cells derived from cisplatin‐treated mice grew rapidly, whereas regrowth of tumor cells from gefitinib‐treated mice was severely diminished. We further demonstrate that expression of EGFR correlates with expression of β–catenin and Nanog in primary tumor specimens from NPC patients. These findings provide mechanistic and preclinical evidence supporting the use of gefitinib alone or in combination with a chemotherapeutic agent in first‐line therapy for patients with NPC. In addition, our results suggest that targeting β–catenin represents a rational clinical modality for patients whose tumors harbor activated EGFR or AKT.</p> </abstract>